New hope for myeloma: Head-to-Head trial of two powerful drugs

This phase 3 study tests whether a new drug, JNJ-79635322, works better than the current treatment teclistamab for people with multiple myeloma that has come back or stopped responding to prior therapies. About 700 adults who have already tried 1 to 3 treatments, including specific standard drugs, will be randomly assigned to one of the two drugs. The main goals are to see which drug leads to more complete remissions and longer time without the cancer growing.